Camena Bioscience Appoints Gregory P. McGuinness as CEO
Internationally recognised business executive with extensive operational experience in life sciences, diagnostics and pharma
Appointment will lead strategic growth plans, including commercialisation of the gSynth® platform for AI-driven antibody discovery, and operational scaling
Camena Bioscience, a pioneer in enzymatic DNA synthesis producing complex, high-fidelity gene constructs for AI-driven antibody discovery, today announced the appointment of Gregory P. McGuinness as Chief Executive Officer. Greg’s appointment will support the Company’s continued growth, driving commercialisation of the gSynth® platform for AI-driven antibody discovery, and operational scaling.
Greg has over 30 years of executive leadership and operational expertise, having successfully commercialised disruptive and foundational technologies across the life sciences and diagnostics markets. His career has been defined by scaling operations, driving product innovation, and executing commercial expansion into global markets. Camena’s proprietary gSynth® technology platform enables researchers to write DNA, including long, complex, and difficult-to-synthesise gene sequences, at scale and with unprecedented accuracy and speed.
